Therapeutic Benefits of Lenalidomide in Hematological Malignancies
Lenalidomide is an immunomodulatory agent, which has action against most of the hematological malignancies. Apart from its immunomodulation, it has other properties such as antiproliferation and antiangiogenesis. It is not only effective in myelodysplastic syndromes and myeloma, recent studies show...
Saved in:
| Main Authors: | Mohammed Shafi Abdulsalam, Durai Mavalavan Vasudevan Manimoliyan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-04-01
|
| Series: | Indian Journal of Medical Specialities |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/INJMS.INJMS_8_19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01) -
Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)